NCT03709953 (Spark-AL003) is a Phase 2 clinical trial of Apatinib in Lung Carcinoma, sponsored by Guangzhou Institute of Respiratory Disease.

Who is sponsoring NCT03709953?

NCT03709953 is sponsored by Guangzhou Institute of Respiratory Disease.

What drugs are being tested in NCT03709953?

Interventions in NCT03709953: Apatinib.

What condition does NCT03709953 study?

NCT03709953 studies Lung Carcinoma.

Is NCT03709953 still recruiting?

NCT03709953 is currently status unknown. Last updated 24 October 2018.

Last reviewed 2018-10-24 · How we verify

NCT03709953: Spark-AL003

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy and Safety of Apatinib as Third-line Therapy for Primary Pulmonary Lymphoepithelioid Carcinoma

Status unknown Phase 2 Last updated 24 October 2018

What this trial tests

Phase 2 trial testing Apatinib in Lung Carcinoma in 33 participants. Status unknown.

Timeline

19 October 2018

Primary endpoint
31 March 2021

30 April 2021

Quick facts

Lead sponsor	Guangzhou Institute of Respiratory Disease
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	33
Start date	19 October 2018
Primary completion	31 March 2021
Estimated completion	30 April 2021
Sites	1 location across China

Drugs / interventions tested

Apatinib (Apatinib) — full drug profile →

Conditions studied

Lung Carcinoma — all drugs for Lung Carcinoma →

Sponsor

Guangzhou Institute of Respiratory Disease

Who can join

Adults 18 to 75, any sex, with Lung Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Currently, there is no standard treatment for primary pulmonary lymphoepithelioid carcinoma. Apatinib is a new kind of Vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitors (TKIs). A disease-control rate of 75% was found in lung cancer patients in a phase II clinical study. Therefore, researchers hope to explore the efficacy and safety of apatinib in the treatment of primary pulmonary lymphoepithelioid carcinoma.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting STAT3 in Cancer Immunotherapy.
Zou S, Tong Q, Liu B, Huang W, et al · · 2020 · cited 787× · PMID 32972405 · DOI 10.1186/s12943-020-01258-7
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery.
Hu Y, Dong Z, Liu K. · · 2024 · cited 159× · PMID 38245798 · DOI 10.1186/s13046-024-02949-5

Verify or expand the search:

Other trials of Apatinib

Trials testing the same drug.

NCT07309419 — A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunothera · Phase 2, PHASE3 · not yet recruiting
NCT07334483 — A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC · Phase 2 · recruiting
NCT07031154 — A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Rese · Phase 2 · not yet recruiting
NCT07294664 — PD1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric Cancer · Phase 2 · recruiting
NCT06893887 — Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma · NA · recruiting

Other recruiting trials for Lung Carcinoma

Currently open trials in the same condition.

NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
NCT07291414 — A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients · NA · recruiting
NCT07285044 — The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Tr · Phase 2 · recruiting
NCT07019675 — A Study of SKB518 in Patients With Lung Cancer · Phase 2 · recruiting
NCT07118176 — Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers · Phase 1 · recruiting

Other Guangzhou Institute of Respiratory Disease trials

Trials by the same sponsor.

NCT07092137 — Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer · Phase 2 · not yet recruiting
NCT06909383 — Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Can · Phase 2 · not yet recruiting
NCT07005999 — Interventional Ablation for Early-stage Lung Cancer · active not recruiting
NCT06739928 — Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC · Phase 2 · recruiting
NCT06715956 — Observational Study of Sputum Inflammation Phenotypes and Clinical Outcomes in Non-Cystic Fibrosis Bronchiectasis · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03709953 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guangzhou Institute of Respiratory Disease
Last refreshed: 24 October 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03709953.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing